SparingVision

🔬🌍 We are thrilled to share our CEO's latest op-ed, "From Promise to Reality: Unlocking the True Business Potential of Genomic Medicine", now published on pharmaphorum. In this compelling piece, Stephane Boissel explores how genomic medicine is transitioning from a groundbreaking promise to a transformative force in healthcare. He shares SparingVision’s bold vision for genomic medicines and a call to action to rethink standard approaches and turn the promise of genomic medicines into a viable business case. 📖 Read the full article here: https://lnkd.in/e9tYs69D #GenomicMedicine #GeneTherapy #Innovation #BlindingRetinalDiseases #Biotech

Just wrapped up the Cowen Inc. Healthcare Conference in Boston! It was great to be in such a vibrant hub of healthcare and innovation, attending alongside my talented colleagues Anjeza Gjino and Pierre-Axel VINOT - Pharm.D, Ph.D. We presented SparingVision's highly differentiared approach to ocular genomics, connected with peers and investors, and gained invaluable insights from thought-provoking panels. A big thank you TD Cowen for putting together such engaging conference. Looking forward to continuing the great conversations and collaborations.

🌟 Exciting News! 🌟 We’re thrilled to announce the appointment of Anjeza Gjino as our new Chief Financial Officer! 🎉https://lnkd.in/eXCy8DMD With extensive experience in the biotech & pharma industry and a proven track record navigating public markets in scaling-up biotech companies, Anjeza brings unparalleled expertise to the team. Her leadership will be instrumental as we continue to progress our gene-independent gene therapies into the clinic and deliver on our mission to bring new hope to patients with blinding retinal diseases. Learn more about our fantastic leadership team here: https://lnkd.in/d6qjeuzW ✨ Please join us in welcoming Anjeza to the SparingVision team! 🚀 #GenomicMedicines #Biotech #blindingretinaldiseases #NewCFO

We’re thrilled to recognize the incredible talent within our team and announce several well-deserved promotions! 🚀 👏 Laure Blouin – Promoted to Senior Director, Medical communication / Clinical Scientist. 👏Caitlin Collin – Promoted to Associate Director, Gene Editing. 👏 Fabien Dorange - Promoted to Senior Director, Analytical Sciences. 👏 Gaelle Fanon - Promoted to Senior Director, Quality Assurance. 👏 Alexis Le Chevallier– Director, Financial Planning & Analysis 👏 Mélanie MARIE, Engineer, PhD, ERT - Promoted to Senior Director, Development sciences. 👏 Nelle Messeca– Promoted to Director, Clinical Operations.   Each of them has demonstrated outstanding dedication, expertise, and passion for advancing ocular genomics programs and making a meaningful impact in our team. We’re so proud of their achievements and excited to see them thrive in their new roles! Please join us in congratulating them! 🎊

✨ A new milestone for ocular gene therapy ✨ A groundbreaking achievement in ocular gene therapy was published in the Lancet this weekend as a gene therapy trial successfully restored vision in blind children with LCA4: https://lnkd.in/gsStmnAu   This milestone is not just a victory for MeiraGTx, but for the entire scientific & patient community working on Inherited Retinal Diseases. Congratulations to the brilliant minds behind this achievement! 👏🔬💙   At SparingVision, we celebrate this incredible progress and we are inspired to push further the boundaries of innovation in ocular genomics. Our lead program SPVN06 is currently in the clinic for patients with moderate RP; our second program, SPVN20, a vision restoration gene-independent gene therapy for patients with advanced RP, should enter the clinic later this year. Together, we are transforming the future of medicine for a future free from blinding retinal diseases.   #GeneTherapy #VisionRestored #BiotechBreakthrough #HopeInSight

Our CEO, Stephane Boissel, had the privilege of participating in a thought-provoking round table on the opportunities and challenges facing biotech in Europe with Laurent Arthaud, Managing Director Bpifrance. Led by Clément Pétreault from Le Point, the discussion explored how collaboration between key stakeholders can shape the future of life sciences on the continent.🔬   💫 It’s clear that Europe has the talent, infrastructure, and ambition to drive biotech breakthroughs that benefit society. However, addressing funding gaps, navigating the regulatory landscape, and accelerating market access remain critical priorities.    A huge thank you to Le Point and Kadans Science Partner for inviting us and creating a platform for such meaningful dialogue. We’re proud to be part of a community that is pushing the boundaries of science and technology. 🚀   Elise Colla Romain Gonzalez Sophie Gournay   #Biotech #ChooseScience #chooseFrance#ParisSaclaySummit #genomicmedicines #innovation #AI

📢 SparingVision announces presentation of SPVN06 safety data at the Macula Society 48th Annual Meeting Professor Isabelle audo presented the latest safety data on SPVN06, our lead investigational gene therapy for retinitis pigmentosa. ✅ Key Findings: ✔️ Favorable safety profile maintained across all patient cohorts ✔️ Up to 12-month follow-up data for low dose and 6-month data for medium dose cohorts (n=6) ✔️ 3-9 month data for high-dose cohort (n=3) ✔️ No significant intraocular inflammation, serious adverse events, or study discontinuations 👉 Read more about this breakthrough: https://lnkd.in/efvDSbvJ #GeneTherapy #RetinalDisease #RetinitisPigmentosa #Ophthalmology #ClinicalTrials

Today is International Day of Women and Girls in Science. Did you know that a significant gender gap has persisted throughout the years at all levels of science, technology, engineering and mathematics (STEM) disciplines all over the world? At SparingVision, we like to recognize the importance of having a diverse team. Hear from some of the women at SparingVision about the passion excitement, challenge and limitless possibility of a career in science. SparingVision is proud to support this initiative. Learn more here: https://lnkd.in/ewY_6ij   #InternationalDayofWomenandGirlsinScience #WomenInSTEM #GenderEquality #GirlsInScience

February is Age-Related Macular Degeneration (AMD) and #LowVisionAwareness Month 👁️ According to NICE - National Institute for Health and Care Excellence, AMD is the most common cause of severe visual impairment in older adults in the developed world, with dry AMD accounting for 85-90 percent of all cases. Geographic Atrophy (GA), is an advanced form of dry AMD which can cause central blind spots and significant vision loss. In the US alone, it is estimated that 1 million people in the United States have GA. (Prevent Blindness).    🧬 Our lead gene-agnostic investigational gene therapy, SPVN06, is aimed at stopping or slowing disease progression in patients affected by IRDs and Geographic Atrophy. 👁️   👉 Find out more about this initiative here: https://lnkd.in/gBYvrnFN   #GenomicMedicines #Ophthalmology #GeneTherapy #GenomeEditing

🚨 Happening today!🚨 Pierre-Axel VINOT - Pharm.D, Ph.D our Director, CMC Portfolio Management, will be speaking today on a panel on the topic of "Innovations and Challenges facing ATMPs"✨ Pierre-Axel will be sharing his expert insights, and how SparingVision is pioneering genomic medicines for blinding retinal diseases. If you're attending, be sure to catch the discussion and connect with him! 👋 #Leadership #ATMPS #oculargenomics #gene therapy #CMC